Targeting von Willebrand disease: the current status and future directions of management therapies

References

• Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood. 1987;69(2):454–459. doi: 10.1182/blood.V69.2.454.454
   PubMed Web of Science ®Google Scholar
• Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4(10):2103–2114. doi: 10.1111/j.1538-7836.2006.02146.x
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Pasalic L. Laboratory diagnosis of von Willebrand disease in the age of the new guidelines: considerations based on geography and resources. Res Pract Thromb Haemost. 2023;7(5):102143. doi: 10.1016/j.rpth.2023.102143
   PubMed Web of Science ®Google Scholar
• James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280–300. doi: 10.1182/bloodadvances.2020003265
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost. 2005;3(12):2619–2626. doi: 10.1111/j.1538-7836.2005.01663.x
   PubMed Web of Science ®Google Scholar
• ISTH/SSC Joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group, Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063–2065.
   PubMed Web of Science ®Google Scholar
• Tosetto A, Castaman G, Rodeghiero F. Assessing bleeding in von Willebrand disease with bleeding score. Blood Rev. 2007;21(2):89–97. doi: 10.1016/j.blre.2006.04.002
   PubMed Web of Science ®Google Scholar
• Kuthiala S, Grabell J, Relke N, et al. Management of heavy menstrual bleeding in women with bleeding disorders in a tertiary care center. Res Pract Thromb Haemost. 2023;7(3):100119. doi: 10.1016/j.rpth.2023.100119
   PubMed Web of Science ®Google Scholar
• Mannucci PM. How I treat patients with von Willebrand disease. Blood. 2001;97(7):1915–1919. doi: 10.1182/blood.V97.7.1915
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Wood AJJ. Treatment of von Willebrand’s disease. N Engl J Med. 2004;351(7):683–694. doi: 10.1056/NEJMra040403
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Franchini M, Castaman G, et al. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus. 2009;7(2):117–126. doi: 10.2450/2008.0052-08
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia. 2000;6(Suppl 1):60–67. doi: 10.1046/j.1365-2516.2000.00059.x
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease. Exp Rev Hematol. 2016;9(9):825–830. doi: 10.1080/17474086.2016.1214070
   PubMed Web of Science ®Google Scholar
• Mannucci PM. New therapies for von Willebrand disease. Blood Adv. 2019;3(21):3481–3487. doi: 10.1182/bloodadvances.2019000368
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Wood AJJ. Hemostatic drugs. N Engl J Med. 1998;339(4):245–253. doi: 10.1056/NEJM199807233390407
   PubMed Web of Science ®Google Scholar
• Castaman G. How I treat von Willebrand disease. Thromb Res. 2020;196:618–625. doi: 10.1016/j.thromres.2020.07.051
   PubMed Web of Science ®Google Scholar
• Castaman G, Linari S. Diagnosis and treatment of von Willebrand disease and rare bleeding disorders. J Clin Med. 2017;6(4):45. doi: 10.3390/jcm6040045
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Chediak J, Hanna W, et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood. 2002;99(2):450–456. doi: 10.1182/blood.V99.2.450
   PubMed Web of Science ®Google Scholar
• Bello IF, Yuste VJ, Molina MQ, et al. Fanhdi, efficacy and safety in von Willebrand’s disease: prospective international study results. Haemophilia. 2007;13(Suppl 5):25–32. doi: 10.1111/j.1365-2516.2007.01570.x
   PubMed Web of Science ®Google Scholar
• Berntorp E, Archey W, Auerswald G, et al. A systematic overview of the first pasteurized VWF/FVIII medicinal product, Haemate P/Humate P: history and clinical performance. Eur J Haematol. 2008;70(Suppl.):3–35. doi: 10.1111/j.1600-0609.2008.01049.x
   Google Scholar
• Gill JC, Ewenstein BM, Thompson AR, et al. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P ®): use of the ristocetin cofactor assay (Vwf: rco) to measure potency and to guide therapy. Haemophilia. 2003;9(6):688–695. doi: 10.1046/j.1351-8216.2003.00816.x
   PubMed Web of Science ®Google Scholar
• Thompson AR, Gill JC, Ewenstein BM, et al. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/von Willebrand factor concentrate (Humate-P). Haemophilia. 2004;10(1):42–51. doi: 10.1046/j.1351-8216.2003.00809.x
   PubMed Web of Science ®Google Scholar
• Lethagen S, Kyrle PA, Castaman G, et al. von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost. 2007;5(7):1420–1430. doi: 10.1111/j.1538-7836.2007.02588.x
   PubMed Web of Science ®Google Scholar
• de Jager NCB, Bukkems LH, Heijdra JM, et al. One piece of the puzzle: population pharmacokinetics of FVIII during perioperative Haemate P®/Humate P® treatment in von Willebrand disease patients. J Thromb Haemost. 2020;18(2):295–305. doi: 10.1111/jth.14652
   PubMed Web of Science ®Google Scholar
• Castaman G, Coppola A, Zanon E, et al. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease. Haemophilia. 2013;19(1):82–88. doi: 10.1111/hae.12005
   PubMed Web of Science ®Google Scholar
• Berntorp E, Wyndyga J, European Wilate Study Group. Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate ® , a new generation von Willebrand factor/factor VIII concentrate. Haemophilia. 2009;15(1):122–130. doi: 10.1111/j.1365-2516.2008.01901.x
   PubMed Web of Science ®Google Scholar
• Lillicrap D, Poon M-C, Walker I, Xie F, Schwartz BA. Association of hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002;87(2):224–230. doi: 10.1055/s-0037-1612977
   PubMedGoogle Scholar
• Federici AB, Castaman G, Franchini M, et al. Clinical use of Haemate P in inherited von Willebrand disease: a cohort study on 100 Italian patients. Haematologica. 2007;92(7):944–951. doi: 10.3324/haematol.11124
   PubMed Web of Science ®Google Scholar
• Rivard GE, Aledort L. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate ® in preventing excessive bleeding during surgery in subjects with von Willebrand disease. Haemophilia. 2008;14(2):271–275. doi: 10.1111/j.1365-2516.2007.01616.x
   PubMed Web of Science ®Google Scholar
• Federici AB, Baudo F, Caracciolo C, et al. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi ®) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia. 2002;8(6):761–767. doi: 10.1046/j.1365-2516.2002.00688.x
   PubMed Web of Science ®Google Scholar
• Hernandez-Navarro F, Quintana M, Jimenez-Yuste V, Alvarez MT, Fernandez-Morata R. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi ® a highly purified, doubly inactivated FVIII/VWF concentrate. Haemophilia. 2008;14(5):963–967. doi: 10.1111/j.1365-2516.2008.01784.x
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Kyrle PA, Schulman S, Di Paola J, Schneppenheim R, Cox Gill J. Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand’s disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. Blood Transfus. 2013;11(4):533–40. doi: 10.2450/2013.0254-12
   PubMed Web of Science ®Google Scholar
• Srivastava A, Serban M, Werner S, et al. Efficacy and safety of a VWF / FVIII concentrate (wilate ®) in inherited von Willebrand disease patients undergoing surgical procedures. Haemophilia. 2017;23(2):264–272. doi: 10.1111/hae.13106
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Von Willebrand disease-associated angiodysplasia: a few answers, still many questions. Br J Haematol. 2013;161(2):177–182. doi: 10.1111/bjh.12272
   PubMed Web of Science ®Google Scholar
• Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis. 2005;16(Suppl Supplement 1):S23–26. doi: 10.1097/01.mbc.0000167659.23262.18
   PubMedGoogle Scholar
• Federici AB. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease. The PRO WILL Stu Haemophilia. 2007;13(s5):15–24. doi: 10.1111/j.1365-2516.2007.01573.x
   PubMedGoogle Scholar
• Holm E, Abshire TC, Bowen J, et al. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand disease prophylaxis network. Blood Coagul Fibrinolysis. 2015;26(4):383–388. doi: 10.1097/MBC.0000000000000257
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Castaman G, Gresele P, et al. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with VWF/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfus. 2019;17(5):391–398. doi: 10.2450/2019.0183-18
   PubMed Web of Science ®Google Scholar
• James PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease. Blood. 2013;122(5):636–640. doi: 10.1182/blood-2012-10-462085
   PubMed Web of Science ®Google Scholar
• Ciavarella N, Schiavoni M, Valenzano E, et al. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand’s disease and an inhibitor against von Willebrand factor. Haemostasis. 1996;26(1):150–154. doi: 10.1159/000217258
   PubMedGoogle Scholar
• Franchini M, Gandini G, Giuffrida A, De Gironcoli M, Federici AB. Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report. Haemophilia. 2008;14(3):645–646. doi: 10.1111/j.1365-2516.2008.01668.x
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Alloantibodies in von Willebrand disease. Semin Thromb Hemost. 2018;44(6):590–594. doi: 10.1055/s-0037-1607440
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost. 2002;88(9):378–379. doi: 10.1055/s-0037-1613225
   PubMedGoogle Scholar
• Goudemand J, Scharrer I, Berntorp E, et al. Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost. 2005;3(10):2219–2227. doi: 10.1111/j.1538-7836.2005.01435.x
   PubMed Web of Science ®Google Scholar
• Borel-Derlon A, Federici AB, Roussel-Robert V, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients. J Thromb Haemost. 2007;5(6):1115–1124. doi: 10.1111/j.1538-7836.2007.02562.x
   PubMed Web of Science ®Google Scholar
• Rugeri L, Benoit R, Desage S, et al. Effectiveness of individualized management using WILFACTIN in patients with von Willebrand disease during surgical procedures: a single-center study. Thromb Res. 2022;220:88–90. doi: 10.1016/j.thromres.2022.09.028
   PubMed Web of Science ®Google Scholar
• Turecek PL, Schrenk G, Rottensteiner H, et al. Structure and function of a recombinant von Willebrand factor drug Candidate. Semin Thromb Hemost. 2010;36(5):510–521. doi: 10.1055/s-0030-1255445
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Von Willebrand factor (Vonvendi): the first recombinant product licensed for the treatment of von Willebrand disease. Expert Rev Hematol. 2016;9(9):825–830. doi: 10.1080/17474086.2016.1214070
   PubMed Web of Science ®Google Scholar
• Turecek PL, Mitterer A, Matthiessen HP, et al. Development of a plasma- and albumin-free recombinant von Willebrand factor. Hamostaseologie. 2009;29(suppl. 1):S32–38. doi: 10.1055/s-0037-1617202
   PubMed Web of Science ®Google Scholar
• Reininger AJ. The function of ultra-large von Willebrand factor multimers in high shear flow controlled by ADAMTS13. Hamostaseologie. 2015;35(3):225–233. doi: 10.5482/HAMO-14-12-0077
   PubMed Web of Science ®Google Scholar
• Tran T, Arnall J, Moore DC, Ward L, Palkimas S, Man L. Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience. J Thromb Thrombolysis. 2020;49(3):431–440. doi: 10.1007/s11239-019-02018-1
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Kempton C, Millar C, et al. rVWF Ad Hoc Study Group. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood. 2013;122(5):648–657. doi: 10.1182/blood-2013-01-479527
   PubMed Web of Science ®Google Scholar
• Gill JC, Castaman G, Wyndiga J, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038–2046. doi: 10.1182/blood-2015-02-629873
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mamaev A, Wang JD, et al. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. J Thromb Haemost. 2019;17(1):52–62. doi: 10.1111/jth.14313
   PubMed Web of Science ®Google Scholar
• Desprez D, Drillaud N, Flaujac C, et al. Efficacy and safety of a recombinant von Willebrand factor treatment in patients with inherited von Willebrand disease requiring surgical procedures. Haemophilia. 2021;27(2):270–276. doi: 10.1111/hae.14242
   PubMed Web of Science ®Google Scholar
• Leebeek FWG, Peyvandi F, Escobar M, et al. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results. Blood. 2022;140(2):89–98. doi: 10.1182/blood.2021014810
   PubMed Web of Science ®Google Scholar
• Lenting PJ, Kizlik-Manson C, Casari C. Towards novel treatment options in von Willebrand disease. Haemophilia. 2022;28(4):5–10. doi: 10.1111/hae.14518
   PubMedGoogle Scholar
• Cefalo MG, Ronco F, Di Felice G, et al. Effectiveness of emicizumab in preventing life-threatening bleeding complications in type 3 von Willebrand disease with inhibitors: a paediatric report. Haemophilia. 2021;27(4):e495–e497. doi: 10.1111/hae.14209
   PubMed Web of Science ®Google Scholar
• Weyand AC, Flood VH, Shavit JA, et al. Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies. Blood Adv. 2019;3(18):2748–2750. doi: 10.1182/bloodadvances.2019000656
   PubMed Web of Science ®Google Scholar
• Thomas VM, Abou-Ismail MY, Lim MY. Off-label use of emicizumab in persons with acquired haemophilia a and von Willebrand disease: a scoping review of the literature. Haemophilia. 2022;28(1):4–17. doi: 10.1111/hae.14450
   PubMed Web of Science ®Google Scholar
• von Drygalski A, Chowdary P, Kulkarni R, et al. XTEND-1 Trial Group. Efanesoctocog alfa prophylaxis for patients with severe hemophilia a. N Engl J Med. 2023;388(4):310–318.
   PubMed Web of Science ®Google Scholar